Status:
COMPLETED
A Study of Bevacizumab (Avastin) in Combination With Dacarbazine in Participants With Unresectable/Metastatic Melanoma
Lead Sponsor:
Hoffmann-La Roche
Conditions:
Malignant Melanoma
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
This study will assess the preliminary anti-tumor activity and safety profile of a combination of bevacizumab and dacarbazine in participants with unresectable/metastatic melanoma not previously treat...
Eligibility Criteria
Inclusion
- Histologically or cytologically confirmed cutaneous malignant melanoma
- Clinical evidence of metastatic disease and/or unresectable regional lymphatic disease and/or extensive in transit recurrent disease
- Measurable and/or evaluable lesions according to RECIST
Exclusion
- Prior interferon alfa and/or cytokine therapy for metastatic disease
- Prior chemotherapy for metastatic disease
- Brain metastases
- Chronic daily treatment with high-dose aspirin (more than 325 milligrams per day)
- Other co-existing malignancies or malignancies diagnosed within the past 5 years with the exception of basal cell cancer or cervical cancer in situ
Key Trial Info
Start Date :
June 30 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 31 2012
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT01164007
Start Date
June 30 2006
End Date
May 31 2012
Last Update
April 21 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Istituto Europeo Di Oncologia
Milan, Lombardy, Italy, 20141